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ity and ﬁt better. As a measure of quality of the ﬁtted model
we have chosen the Deviance Information Criteria (DIC). The
improvement in the deviance of the model for the number of
principles per patient is of 1790 and in DIC of 1760. The maps
reveal geographical inequalities and zones with greater average
values. CONCLUSION: The Bayesian hierarchical models have
been a very useful tool for incorporating geographical informa-
tion in the analysis of pharmacological prescription data. They
allow mapping spatial components expressing the trend of that
geographical variation.
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OBJECTIVES: Pharmacogenetics holds the promise of pre-
venting adverse drug events (ADRs) but the diffusion of these
diagnostic testsis still limited. Assessing cost-effectiveness of
pharmacogenetic interventions, a key to successful clinical imple-
mentation, requires access to data on ADRs and related costs
which are not readily available. This study focuses on ADRs
induced by azathioprine (AZA) treatment in Rheumatoid Arthri-
tis and Inﬂammatory Bowel Disease patients, for whom there is
a recognized association between the occurrence of severe neu-
tropenia and the diminished activity of TPMT. The study aims at
evaluating the availability and quality of cost data related to: (i)
the treatment and management of ADRs induced by AZA and (ii)
the use of TPMT diagnostic kits in an average laboratory. The
overall objective is to review the possibility of building a cost-
effectiveness model on European data. METHODS: A literature
review was conducted on PubMED and Embase databases.. The
clinical path for the management of AZA-induced ADRs was
elaborated with an international panel of gastroenterologists/
rheumatologists. RESULTS: Very few studies describe costs of
treating ADRs induced by AZA. When present, costs are rarely
collected empirically but derived from national tariff databases
or from a single health care organization, resulting in a large
variability. Reported costs are only direct, disregarding produc-
tivity losses, while ADRs often require hospitalization. Direct
annual costs for ADRs range from €476 to €5505. It is equally
difﬁcult to identify solid data on the costs o TPMT diagnostic
tests in an average European laboratory, with estimates between
70€ and 130€. CONCLUSION: Cost-effectiveness data might
inﬂuence the degree of conﬁdence of health care organizations in
adopting new technologies. Published economic studies that
evaluate TPMT diagnostic tests and the costs they might prevent
are still rather weak. Prospective economic studies, that system-
atically include the evaluation of ADR costs, are urgently needed.
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OBJECTIVES: To evaluate switching patterns among anti-tumor
necrosis factor therapies (anti-TNFs) in rheumatoid arthritis
(RA) patients. METHODS: A retrospective patient chart review
study was conducted in six rheumatology clinics across the US.
The ﬁrst anti-TNF encounter among RA patients between 2002
and 2004 was identiﬁed. Patients were required to have a
minimum of 12 months of continuous records prior to and
following their index biologic date. Three mutually exclusive
cohorts were developed based on biologic therapy: inﬂiximab,
etanercept or adalimumab. Switching was deﬁned as discontinu-
ation of the index anti-TNF and initiation of another anti-TNF
agent. The rates of switching and time before switching were
examined. RESULTS: Of 496 patients analyzed, 266 (53.6%)
received inﬂiximab, 146 (29.4%) received etanercept, and 84
(14.1%) received adalimumab. 74% of patients were female,
with an average age of 56.1 years. Overall, 87 (17.5%) patients
switched anti-TNF therapy during the follow-up period.
Patients in the inﬂiximab group had a lower switch rate (31
patients, 11.7%) compared with patients in the etanercept (38
patients, 26%) and adalimumab (18 patients, 21.4%) groups.
Chi-Square analyses indicated the differences among three
groups were statistically signiﬁcant (p < 0.001). The inﬂiximab
group had a longer average time before switching (342 days),
compared with those in the etanercept (266 days) and adali-
mumab (341 days) groups; (p = ns). Lack of effectiveness and
safety concerns were the most common reasons for switching
(28.6%). CONCLUSION: The switching rate and time before
switching are important measures of the effectiveness of RA
treatment in real world practice. This chart review study found
that inﬂiximab is associated with a lower switching rate and
longer time before switching, as compared with etanercept
and adalimumab, both of which had higher switching rates and
shorter time to switching. Further studies to evaluate the asso-
ciation of switching with clinical, economic, and humanistic
outcomes are recommended.
ARTHRITIS—Methods and Concepts
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OBJECTIVES: Analysis of functional data from longitudinal
studies is usually complicated by missing data. The use of
repeated measures ANOVA for statistical analysis tends to
decrease the sample size and thus affect power and signiﬁcance
of the results. The present study aims to address this problem
with use of hierarchical regression or multilevel modeling.
METHODS: We analysed functional results of 4777 patients
following hip resurfacing arthroplasty. These patients were fol-
lowed annually using Harris Hip score and Merle d’Aubigné
score. Individual domains of Pain, mobility and range of move-
ment were recorded. The scores comprised a follow up period of
nine years with some missing values. The data was analysed
using multilevel techniques in statistical package SYSTAT 11.0.
Model was ﬁtted at two levels, with level one being the scores
and level two the patients. RESULTS: In all the domains of
function, pain and movement, pre operative score and gender
were signiﬁcantly associated with post operative hip function
(p <= 0.05). A better pre op score predicted a better post op score
and male gender was associated with better overall function.
There was a consistent inverse relationship of overall functional
improvement with individual domains of pain and movement.
This implied that a good pre-operative pain score will have less
improvement over time as compared to a poor pre-operative pain
score. There was no signiﬁcant effect of age on the overall func-
tional results (p = 0.492). CONCLUSION: Functional outcome
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following hip resurfacing arthroplasty is related to individual
changes over time. Multilevel analysis is a useful approach to
study repeated measures data with missing values.
ARTHRITIS—Patient Reported Outcomes
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OBJECTIVES: To investigate the presence and impact of
response shift (RS) in HRQoL among patients undergoing total
knee replacement (TKR) and explore factors associated with RS.
METHODS: HRQoL of TKR patients was assessed by SF-6D at
0-month (just before surgery: pre-test1), 6 months (pre-test2) and
18 months after surgery (post-test). At 18-month, HRQoL at
0-month and 6-month was evaluated again by “then-test”
approach. RS was calculated as the score difference between
corresponding pre- and then-test. Descriptive analysis was used
for demographics, medical information and satisfaction with
knee surgery (on a 0–10 Likert scale). Wilcoxon Signed Rank
tests were used for comparisons of RS at 0-month and 6-month.
Relationships between RS and external variables were investi-
gated by Mann-Whitney, Kruskal-Wallis tests or Spearman’s cor-
relation. Multiple liner regression (MLR) models were used to
explore factors potentially impacting RS. Unless speciﬁed,
median (interquartile range) was reported and signiﬁcance level
was set at 0.01. RESULTS: Data were analyzed from 74 subjects
[mean (SD) age 68.9 (7.9) years, 81% female, 92% with less than
12 years of education, 72% with acute and 68% with chronic
illness, 10% with past knee surgery history, mean (SD) surgery
satisfaction of 8.0 (1.3)]. SF-6D scores for then-tests at 0-month
[0.48 (0.42, 0.49)] and 6-month [0.72 (0.66, 0.79)] were signiﬁ-
cantly different from respective pre-test scores [0.61 (0.58, 0.68)
at 0-month, 0.69 (0.63, 0.72) at 6-month], both indicating pres-
ence of RS. RS at 0-month was signiﬁcantly larger than that at
6-month. RS at 0-month was not affected by demographic or
medical variables. RS at 6-month was greater in subjects with
higher education (p < 0.01, 16% of variance in MLR). CON-
CLUSION: RS was present and impacted HRQoL assessment
among patients undergoing TKR both just prior to and 6 months
after surgery. RS investigation is thus suggested to be performed
during HRQoL evaluations.
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OBJECTIVES: The aim of this study was to validate Oswestry
hip score which was developed as a patient-completed self-
assessment to provide both Harris and Merle d’Aubigne hip
score with added content to estimate hip range of motion.
METHODS: A total of 161 patients completed the Oswestry hip
score, WOMAC Index, Harris hip score (HHS) and the Oxford
hip score (OHS at two different occasions. Validity was tested by
comparing the domains of the Oswestry hip score to WOMAC,
HHS and OHS. RESULTS: The reliability of this new score was
established by the test-retest method. Cronbach’s alpha was 0.7,
which is considered a good measure of internal consistency.
Content validity of the Oswestry hip score was established by the
validated domains of pain, function and range of motion of HHS
and Merle score. Analysis of frequency of response distribution
showed normal ﬂoor and ceiling effect for any of the domains of
the Oswestry hip score. Multimethod multitrait matrix analysis
was used to establish the construct validity of the Oswestry hip
score. There was good correlation between pain and function
domains (p < 0.001). Moderate correlation was found among
clinical assessment of hip movement and movement domains of
Oswestry hip score (Pearson’s r = 0.55; p0.001). CONCLU-
SION: A positive construct validity and high correlation with
WOMAC, Oxford Hip Score and Harris hip score shows that the
Oswestry hip score can give an adequate measure of hip joint
function. It can be completed by patients themselves and is
therefore ideal for long-term and large scale collection of clinical
outcome data.
DIABETES—Clinical Outcomes Studies
PDB1
GLYCEMIC CONTROL GOAL ATTAINMENT AMONGTYPE 2
DIABETIC PATIENTS WHO INITIATED ORAL COMBINATION
THERAPY IN HUNGARY
György B1, Hungarian RG2, Nagy L3, Erdesz D3,Yin D4,
Krishnarajah G4
1Bajcsy-Zsilinszly Hospital, MaglódiMaglódi, Hungary, 2Hungarian
RECAP Group, NA, Hungary, 3MSD Hungary, Budapest, Hungary,
4Merck & Co., Inc,Whitehouse Station, NJ, USA
OBJECTIVES: To assess the level of adequate glycemic control
in real life practice settings in Hungary in adult patients with type
2 diabetes mellitus (T2DM) who added a sulfonylurea (SU)
or glitazone (PPAR) to ongoing metformin(MF) monotherapy.
METHODS: Retrospective clinical chart reviews and patient
surveys at the point of visit (January 2006–March 2007) were
conducted in Hungary. Patients were °Ý30 years of age at time of
T2DM diagnosis and added a SU or PPAR to previous MF
monotherapy irrespective of whether those drugs were discon-
tinued afterwards. Information on A1C, medication use and
co-morbid conditions was extracted from clinical charts, for up
to a 7 month baseline period (MF monotherapy) and for a
minimum of one year follow-up period (between therapy
addition and date of survey). Glycemic goal attainment at
A1C < 6.5% was assessed according to the IDF (2005) recom-
mendations using the last available A1c value during follow-up.
RESULTS: In total, 401 patients (85% SU + MF and 15%
PPAR + MF) of which 52.1% males, were recruited. For the
SU + MF and PPAR + MF groups respectively: mean age was
61.0(SD = 9.3) and 57.9(SD = 11.4) years; duration of diabetes
was 7.53(SD = 5.1) and 6.6(SD = 4.2) years; A1C during MF
monotherapy was 8.4(SD = 1.6) and 7.6(SD = 1.4); A1C since
combination therapy was 7.9(SD = 1.3) and 7.1(SD = 1.3).
Patients at goal after addition of SU was 21.7% and 26.7% were
at goal after addition of PPAR. In total, 14.2% initiated insulin
since the addition of SU to MF, 3.3% initiated insulin since the
addition of PPAR to MF. CONCLUSION: Several differences
were seen between the groups who added SU or PPAR to MF,
including age, duration of diabetes and A1C values. In both
groups, approximately three quarters of patients with T2DM
failed to attain glycemic control goal since initiating oral combi-
nation therapy.
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